ORIC · XBRL financial data

Oric Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ORIC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
General and administrative	13,422	22,013	25,087	25,608	28,823	33,186
Total operating expenses	74,186	78,871	91,767	110,780	142,895	143,004
Operating income (loss)	(74,186)	(78,871)	(91,767)	(110,780)	(142,895)	(143,004)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(73,703)	(78,715)	(89,122)	(100,697)	(127,847)	(129,468)
Earnings per share, basic USD per share	—	(2.07)	(2.25)	(1.96)	(1.83)	(1.47)
Earnings per share, diluted USD per share	—	(2.07)	(2.25)	(1.96)	(1.83)	(1.47)
Weighted average shares, basic thousands of shares	—	37,954	39,655	51,451	69,728	87,794
Weighted average shares, diluted thousands of shares	—	37,954	39,655	51,451	69,728	87,794

Fiscal years (ORIC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	78,446	226,006	66,840	23,384	59,406	45,669
Marketable securities	215,154	10,973	139,432	184,803	196,554	235,819
Marketable securities, non-current	0	43,386	21,951	26,852	0	110,762
Prepaid and other current assets	3,097	3,543	4,185	4,410	6,290	6,978
Total current assets	296,697	240,522	210,457	212,597	262,250	288,466
Property and equipment, net	1,981	2,413	3,253	2,862	2,924	2,415
Right-of-use asset	—	11,800	11,000	9,144	8,380	6,658
Total assets	298,997	298,642	247,178	252,007	274,142	408,890
Accounts payable	757	1,886	1,320	944	1,548	3,824
Accrued liabilities	8,245	13,265	14,068	19,514	23,298	16,593
Total current liabilities	9,002	15,151	15,388	20,458	24,846	20,417
Lease liability, non-current	—	10,500	9,400	7,461	6,174	4,111
Total liabilities	9,221	25,666	24,827	27,919	31,020	24,528
Accumulated deficit	(166,393)	(245,108)	(334,230)	(434,927)	(562,774)	(692,242)
Total stockholders' equity	289,776	272,976	222,351	224,088	243,122	384,362
Total liabilities and equity	298,997	298,642	247,178	252,007	274,142	408,890
Common shares outstanding (cover page) thousands of shares	36,695	39,434	45,091	67,376	71,027	100,358

Fiscal years (ORIC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(73,703)	(78,715)	(89,122)	(100,697)	(127,847)	(129,468)
Stock-based compensation	5,278	12,853	14,460	15,226	20,213	25,037
Net cash from operating activities	(45,268)	(59,541)	(75,143)	(85,688)	(112,662)	(110,970)
Purchases of property and equipment	667	939	2,078	849	1,188	712
Net cash from investing activities	(215,959)	158,435	(109,248)	(43,403)	22,137	(148,031)
Proceeds from issuing common stock	133,308	50,000	25,000	85,000	125,000	244,369
Net cash from financing activities	250,514	49,134	25,225	85,658	126,547	245,264
Net change in cash	(10,713)	148,028	(159,166)	(43,433)	36,022	(13,737)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Oric Pharmaceuticals	37,483	not reported	(31,605)*	103.7M	12.3 quarters	Q2 FY26 10-QJun 30, 2026
Geron	69,179	60,190	10,267*	644.2M	—	Q3 FY26 10-QSep 30, 2026
Intellia Therapeutics	156,098	7,163	(85,430)*	140.4M	4.9 quarters	Q3 FY26 10-QSep 30, 2026
Wave Life Sciences	197,315	13,158	(60,142)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
CorMedix	256,692	101,931	86,237*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Niagen Bioscience	69,509	27,192	2,625*	79.2M	—	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720,242	673,064	615,631*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Ardelyx	46,317	127,655	2,171*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	144,797	216,339	86,536*	31.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 12:05 AM ET. The filing on SEC.gov is the record.